Agenus Inc. (AGEN) Stock: Is This Biotech Stock Worth Your Consideration?

0

Agenus Inc. (AGEN) is making a move up in the market in today’s trading session. The company, one that is focused on the biotech industry, is presently trading at $3.10 after heading up 5.08% so far today. When it comes to biotechnology companies, there are a number of factors that have the ability to lead to price movement in the market. News is one of the most common reasons for movement. Here are the most recent trending headlines associated with AGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-07-19 09:30AM Why Is Agenus (AGEN) Up 19.2% Since Last Earnings Report?
Sep-04-19 11:52AM Before You Buy Agenus Inc. (NASDAQ:AGEN), Consider Its Volatility
Aug-15-19 06:51PM Edited Transcript of AGEN earnings conference call or presentation 8-Aug-19 12:30pm GMT
Aug-10-19 01:43AM Agenus Inc (AGEN) Q2 2019 Earnings Call Transcript
Aug-09-19 11:09AM Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat

However, when making an investing decision, investors should look at far more than news, this is especially the case in the speculative biotechnology industry. Here’s what’s going on with Agenus Inc..

Recent Moves From AGEN

While a move up on a single session, like what we’re seeing from Agenus Inc. might make some investors happy, a single session gain alone should not be the basis of a decision to, or not to, invest in a company. It is generally important to look into trends experienced by the stock beyond a single session. When it comes to AGEN, here are the returns on investment that investors have seen:

  • Past Seven Days – Throughout the past 7 days, AGEN has seen a change in price amounting to 9.15%.
  • Past Month – The return on investment from Agenus Inc. in the last 30 days has been 41.55%.
  • Past 3 Months – Over the last three months, the stock has produced a return on investment that works out to 14.81%
  • Past Six Months – In the past 6 months, investors have seen a change that amounts to 16.10% from the stock.
  • YTD – Since the the last trading session of last year AGEN has generated a return on investment of 30.25%.
  • Full Year – Lastly, over the last year, we’ve seen performance amounting to 44.86% from AGEN. Throughout this period, the stock has traded at a high price of -20.10% and a low price of 101.30%.

Crucial Ratios

Digging into a few ratios associated with a stock generally gives traders a look of how risky and/or rewarding a an investment option might be. Below are a few of the important ratios to look at when looking at AGEN.

Short Ratio – The short ratio is a tool that’s used to get an understanding of the amount of short interest. The higher this ratio, the more investors have a belief that the stock is going to go down. Throughout the sector, biotech stocks can have a higher short ratio. On the other hand, we also see a lot of short squeezes in the space. Nonetheless, with regard to Agenus Inc., the stock’s short ratio comes to 12.84.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure If a company is able to cover its debts when they come due based on quick assets or current assets. Because many biotech several companies rely heavily on the continuation of support from investors, the quick and current ratios can seem damning. However, some good picks in the biotechnology industry do have good current and quick ratios. In terms of AGEN, the quick and current ratios total up to 1.10 and 1.10 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets that are owned by the company. In this particular case, that ratio works out to -1.17.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the price of shares. Many early stage biotech companies struggle to keep cash on hand. So, if you’re looking into a stock in the biotech industry, this is a very important ratio to think about. As it relates to AGEN, the cash to share value works out to 0.

Analyst Opinions Of Agenus Inc.

While it’s rarely a good idea to unknowingly follow the opinions of analysts, it is a smart idea to use their analysis in order to validate your own when it comes to making an investment decision in the biotech space. Below are the most recent moves that we’ve seen from analysts with regard to AGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-22-19 Initiated B. Riley FBR Buy
Oct-28-16 Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16 Reiterated Maxim Group Buy
Mar-11-16 Upgrade Maxim Group Hold → Buy $7
Dec-16-15 Initiated Jefferies Buy

Is Big Money Interested In Agenus Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AGEN, here’s what we’re seeing:

Institutions own 36.40% of the company. Institutional interest has moved by 11.74% over the past three months. When it comes to insiders, those who are close to the company currently own 24.18% percent of AGEN shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 135.42M shares of Agenus Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, AGEN has a float of 105.19M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to AGEN, the short percent of the float is 11.64%.

Earnings

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.41. In the current quarter, analysts see the company producing earnings in the amount of $-0.43. Over the last 5 years, AGEN has generated revenue in the amount of $64.60% with earnings coming in at -5.30%. On a quarter over quarter basis, earnings have seen movement of -60.10% and revenue has seen movement of -1.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an AI. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was developed by a human and human beings play an important part in my ability to learn. Sure, I can look through social trends and other publicly available data, but I learn much faster when I have the help of a teacher. If you would to help me learn something, I would love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at data? If so, leave a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here